KAOPECTATE TABLETS 600MG 600 MG — DIN 00730955
ATTAPULGITE (ACTIVATED) : 600 MG · THE UPJOHN COMPANY OF CANADA · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is KAOPECTATE TABLETS 600MG?
KAOPECTATE TABLETS 600MG 600 MG contains ATTAPULGITE (ACTIVATED) : 600 MG. It is listed in the Health Canada Drug Product Database under DIN 00730955, held by THE UPJOHN COMPANY OF CANADA, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 10-Sep-1996. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
Is there a generic Attapulgite in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
3 holders have a Canadian DIN containing Attapulgite, across 9 DINs, of which 0 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| UPJOHN CONSUMER PRODUCTS COMPANY | 5 | 0 | CHILDREN'S KAOPECTATE SUS 600MG/15ML, KAOPECTATE CHEWABLE TAB 300MG, KAOPECTATE EXTRA STRENGTH SUS, KAOPECTATE EXTRA STRENGTH TAB 750MG, KAOPECTATE LIQ 600MG/15ML | No marketed DIN |
| JOHNSON & JOHNSON - MERCK CONSUMER PHARMACEUTICALS OF CANADA | 3 | 0 | EXTRA STRENGTH KAOPECTATE TABLETS 750MG, KAOPECTATE CHEWABLE TABLETS 300MG, KAOPECTATE TABLET - 600MG | No marketed DIN |
| THE UPJOHN COMPANY OF CANADA | 1 | 0 | KAOPECTATE TABLETS 600MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 600 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Attapulgite |
|---|---|
| ATC code | A07BC04 |
| AHFS class | 88:28.01* ; See footnote |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00730955 |
|---|---|
| DIN (unpadded, as printed on some documents) | 730955 |
| Brand name | KAOPECTATE TABLETS 600MG |
| Generic / active ingredient | ATTAPULGITE (ACTIVATED) : 600 MG |
| Market authorization holder | THE UPJOHN COMPANY OF CANADA |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| ATC code | A07BC04 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A07BC |
| Current status | CANCELLED POST MARKET |
| Status date | 10-Sep-1996 |
| Original market date | 1985-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 9 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CHILDREN'S KAOPECTATE SUS 600MG/15ML | 600 MG / 15 ML | SUSPENSION | UPJOHN CONSUMER PRODUCTS COMPANY | CANCELLED POST MARKET | 01951165 |
| EXTRA STRENGTH KAOPECTATE TABLETS 750MG | 750 MG | TABLET | JOHNSON & JOHNSON - MERCK CONSUMER PHARMACEUTICALS OF CANADA | CANCELLED POST MARKET | 02229949 |
| KAOPECTATE CHEWABLE TAB 300MG | 300 MG | TABLET | UPJOHN CONSUMER PRODUCTS COMPANY | CANCELLED POST MARKET | 00875058 |
| KAOPECTATE CHEWABLE TABLETS 300MG | 300 MG | TABLET | JOHNSON & JOHNSON - MERCK CONSUMER PHARMACEUTICALS OF CANADA | CANCELLED POST MARKET | 02229948 |
| KAOPECTATE EXTRA STRENGTH SUS | 750 MG / 15 ML | SUSPENSION | UPJOHN CONSUMER PRODUCTS COMPANY | CANCELLED POST MARKET | 01942212 |
| KAOPECTATE EXTRA STRENGTH TAB 750MG | 750 MG | TABLET | UPJOHN CONSUMER PRODUCTS COMPANY | CANCELLED POST MARKET | 00822531 |
| KAOPECTATE LIQ 600MG/15ML | 600 MG / 15 ML | LIQUID | UPJOHN CONSUMER PRODUCTS COMPANY | CANCELLED POST MARKET | 00836656 |
| KAOPECTATE TABLET - 600MG | 600 MG | TABLET | JOHNSON & JOHNSON - MERCK CONSUMER PHARMACEUTICALS OF CANADA | CANCELLED POST MARKET | 02229953 |
2 · Same class — other molecules in ATC A07BC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Attapulgite | CHILDREN'S KAOPECTATE SUS 600MG/15ML · EXTRA STRENGTH KAOPECTATE TABLETS 750MG · KAOPECTATE CHEWABLE TAB 300MG · KAOPECTATE CHEWABLE TABLETS 300MG · +5 more | 9 | 0 | Not in Canada |
| Combinations | DIARET LIQ · DIAREX · DONNAGEL-MB SUS · KAOLIN AND PECTIN SUSP · +2 more | 6 | 0 | Not in Canada |
| Attapulgite, Combinations | DIARET TAB · DIAREX TAB | 2 | 0 | Not in Canada |
| Kaolin, Combinations | DONNAGEL LIQ | 2 | 0 | Not in Canada |
| Pectin, Combinations | WATKINS SETTELZ | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A07B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A07BB | Bismuth Preparations | 55 | 12 |
| A07BA | Charcoal Preparations · Medicinal Charcoal · Medicinal Charcoal, Combinations | 34 | 10 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.